Friday 6 November 2026
Export AHCO’s income statement to Excel — free account
AdaptHealth Corp.
AHCO Healthcare Medical Devices
- Revenue
- +10.9%
- EPS
- −758.8%
- Free cash flow
- −23.6%
- Total debt
- +6.85%
Quarter to September 2026, against a year earlier
7.33
0.08
−1.08%
Follow AHCO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.40 | 0.47 | 0.42 | 0.22 | |
P/FCF ratio |
6.14 | 8.36 | 14.31 | 9.23 | |
P/Operating CF |
7.35 | 17.24 | 9.76 | 4.91 | |
P/B ratio |
0.88 | 1.07 | 1.02 | 0.62 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.89 | 1.00 | 0.98 | 0.75 | |
EV/EBITDA |
4.96 | 5.69 | 5.78 | 4.51 | |
EV/Operating CF |
5.00 | 5.70 | 5.64 | 4.48 | |
EV/FCF |
13.71 | 17.69 | 33.18 | 31.11 | |
Quick Ratio |
0.67 | 0.59 | 0.61 | 0.64 | |
Current Ratio |
1.02 | 0.92 | 1.12 | 1.13 | |
Net Debt/EBITDA |
8.97 | 15.96 | 14.62 | 12.26 | |
Debt/Assets |
40.98% | 41.89% | 44.08% | 45.35% | |
Debt/Equity |
1.16 | 1.22 | 1.38 | 1.54 | |
Asset Turnover |
0.77 | 0.77 | 0.78 | 0.80 | |
Operating CF/Net income |
(1.78) | (5.84) | (1.08) | (1.02) | |
Capex/Depreciation |
(0.46) | (1.11) | (0.63) | (0.35) | |
Interest Coverage |
(1.69) | 0.21 | (5.26) | (5.45) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
9.85% | 11.70% | 12.98% | 11.89% | |
Intangible Assets out of Total Assets |
0.58 | 0.60 | 0.55 | 0.52 | |
Share Based Compensation of Revenue |
0.45% | 0.80% | 0.75% | 0.16% | |
Graham Net Nets |
(1.53) | (1.38) | (1.52) | (2.77) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.42%) | (5.13%) | (16.31%) | (53.01%) | |
Free Cash Flow Yield |
16.30% | 11.97% | 6.99% | 10.84% | |
Revenue per Share |
8.42 | 6.04 | 5.44 | 5.47 | |
Operating CF per Share |
1.36 | 0.69 | 1.07 | 1.15 | |
Capex per Share |
(0.77) | (0.88) | (1.22) | (0.77) | |
Free Cash Flow per Share |
0.59 | (0.19) | (0.15) | 0.37 | |
Cash per Share |
0.79 | 0.35 | 0.32 | 0.59 | |
Shareholders Equity per Share |
11.29 | 11.15 | 10.18 | 9.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.29 | 11.15 | 10.18 | 9.04 | |
Free Cash Flow |
79.29 | (26.05) | (20.94) | 51.06 | |
Working Capital |
16.51 | (55.81) | 88.26 | 94.27 | |
Capital Expenditures |
(103.90) | (119.77) | (166.24) | (105.52) | |
Net Current Asset Value |
(2,061.35) | (2,222.05) | (2,157.14) | (2,128.39) | |
EV/EBIT |
33.11 | 46.74 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.15 | 0.22 | 0.14 | |
Price to Operating Income |
14.81 | 22.08 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
389.46 | 405.21 | 391.99 | 388.09 | |
Average Payables |
495.84 | 511.29 | 526.75 | 561.19 | |
Average Inventory |
127.37 | 144.28 | 127.17 | 130.49 | |
Average Assets |
4,401.76 | 4,430.68 | 4,345.85 | 4,292.12 | |
Average Common Equity |
1,552.22 | 1,544.17 | 1,490.19 | 1,429.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026